U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H14N8O4S3
Molecular Weight 454.507
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFAZOLIN

SMILES

[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN4C=NN=N4)C(O)=O

InChI

InChIKey=MLYYVTUWGNIJIB-BXKDBHETSA-N
InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H14N8O4S3
Molecular Weight 454.507
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, cefazolin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. Cefazolin is used to treat bacterial infections of the skin, moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. This drug also can be used for perioperative prophylaxis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.18540796E11
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.18540796E11
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.18540796E11
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.18540796E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
280.9 μg/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFAZOLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
509.9 μg × h/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFAZOLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.01 h
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFAZOLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
healthy, 21 to 35 years
n = 7
Health Status: healthy
Age Group: 21 to 35 years
Sex: M
Population Size: 7
Sources:
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (14.3%)
Sources:
1.5 g 8 times / day multiple, intravenous
Highest studied dose
Dose: 1.5 g, 8 times / day
Route: intravenous
Route: multiple
Dose: 1.5 g, 8 times / day
Sources:
unhealthy, 21-34 years
n = 4
Health Status: unhealthy
Condition: endocarditis
Age Group: 21-34 years
Sex: M+F
Population Size: 4
Sources:
1 g 4 times / day multiple, intravenous
Recommended
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
healthy, 75 years
n = 1
Health Status: healthy
Age Group: 75 years
Sex: F
Population Size: 1
Sources:
Other AEs: Pseudomembranous colitis...
Other AEs:
Pseudomembranous colitis
Sources:
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy
n = 75
Health Status: unhealthy
Condition: closed fractures
Population Size: 75
Sources:
Other AEs: Infection...
Other AEs:
Infection (serious, 15 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Rash 14.3%
Disc. AE
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
healthy, 21 to 35 years
n = 7
Health Status: healthy
Age Group: 21 to 35 years
Sex: M
Population Size: 7
Sources:
Pseudomembranous colitis
1 g 4 times / day multiple, intravenous
Recommended
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
healthy, 75 years
n = 1
Health Status: healthy
Age Group: 75 years
Sex: F
Population Size: 1
Sources:
Infection serious, 15 patients
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy
n = 75
Health Status: unhealthy
Condition: closed fractures
Population Size: 75
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 1740 uM]
yes [Ki 180 uM]
yes [Ki 550 uM]
PubMed

PubMed

TitleDatePubMed
Double-blind comparison of phlebitis produced by cefazolin versus cephalothin.
1975 Apr
Relationship between the transport and toxicity of cephalosporins in the kidney.
1975 Aug
Hemolysis induced by cefazolin and cephalothin in a patient with penicillin sensitivity.
1978 May-Jun
IgE antibodies for penicillins and cephalosporins in rats. III. Antigenic specificity of rat anti-cephalosporin-OvA IgE sera.
1981 Jan
Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
1999 Nov 5
Amykacin-related apneic episode in an infant on peritoneal dialysis.
2000 Apr
Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children.
2001
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Fine structural recognition specificities of IgE antibodies distinguishing amoxicilloyl and amoxicillanyl determinants in allergic subjects.
2001 Sep-Oct
Effect of water content on the solid-state stability in two isomorphic clathrates of cephalosporin: cefazolin sodium pentahydrate (alpha form) and FK041 hydrate.
2002 Jun
Fluorimetric determination of some antibiotics in raw material and dosage forms through ternary complex formation with terbium (Tb(3+)).
2003 Aug 21
Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis.
2004 Sep
Efficacy of a non-vancomycin-based peritoneal dialysis peritonitis protocol.
2005 Apr
Effect of isoniazid on the pharmacodynamics of cefazolin-induced seizures in rats.
2005 Apr
Graft infectivity of rifampin and silver-bonded polyester grafts to MRSA contamination.
2005 Sep-Oct
Chemiluminescence flow-injection analysis of beta-lactam antibiotics using the luminol-permanganate reaction.
2006 Jul-Aug
Influence of ascorbic acid on BUN, creatinine, resistive index in canine renal ischemia-reperfusion injury.
2006 Mar
[Simultaneous spectrophotometric determination of certain beta-lactam antibiotics in rabbit serum using multivariate calibration methods].
2007 Feb
[Retropharyngeal abscesses: a retrospective analysis of 10 patients].
2008 Sep-Oct
Kinetic spectrofluorimetric determination of certain cephalosporins in human plasma.
2009 Feb 15
The effects of methylprednisolone and cefazolin sodium on antioxidant status in experimentally induced maxillary sinusitis.
2009 Oct
Laser-induced silver nanoparticles on titanium oxide for photocatalytic degradation of methylene blue.
2009 Oct 29
Evaluating intra- and inter-examiner reproducibility in histometric measurement: one-wall intrabony periodontal defects in beagle dogs.
2010 Aug
Non-syndromic multiple supernumerary teeth in a family unit with a normal karyotype: case report.
2010 Nov 5
Investigation of the toxic functional group of cephalosporins by zebrafish embryo toxicity test.
2010 Oct
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

Moderate to severe infections: 500 mg to 1 gram, every 6 to 8 hours; mild infections caused by susceptible gram-positive cocci: 250 mg to 500 mg, every 8 hours; acute, uncomplicated urinary tract infections: 1 gram, every 12 hours; Pneumococcal pneumonia: 500 mg, every 12 hours; Severe, life threatening infections (e.g., endocarditis, septicemia): 1 gram to 1.5 grams, every 6 hours
Route of Administration: Other
In Vitro Use Guide
Susceptibilities of 259 isolates of pathogenic bacteria to cefazolin were measured by broth and agar dilution procedures. Beta-hemolytic streptococci were inhibited by 0.25 mug/ml, whereas Staphylococcus aureus and alphahemolytic streptococci were inhibited by 2.0 mug/ml. Enterococci were resistant to less than 32 mug/ml. Wide variation was seen with gram-negative species. Most isolates of Klebsiella species and Proteus mirabilis were inhibited by 4.0 or 8.0 mug/ml. Escherichia coli were less susceptible, and most isolates of Pseudomonas aeruginosa, Serratia species, and Enterobacter species were resistant to 128 mug/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 16 16:50:17 UTC 2022
Edited
by admin
on Fri Dec 16 16:50:17 UTC 2022
Record UNII
IHS69L0Y4T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFAZOLIN
HSDB   INN   MART.   MI   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
CEFAZOLIN [MI]
Common Name English
cefazolin [INN]
Common Name English
CEFAZOLIN [USP MONOGRAPH]
Common Name English
Cefazolin [WHO-DD]
Common Name English
(6R,7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Systematic Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 3-(((5-METHYL-1,3,4-THIADIAZOL-2-YL)THIO)METHYL)-8-OXO-7-(((1H-TETRAZOL-1-YL)ACETYL)AMINO)-(6R-TRANS)
Common Name English
J01DB04
Code English
CEFAZOLIN [VANDF]
Common Name English
CEFAZOLIN [HSDB]
Common Name English
CEFAZOLIN [MART.]
Common Name English
CEFAZOLIN [USP-RS]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
LIVERTOX NBK548358
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
LIVERTOX NBK547862
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
WHO-ATC J01DB04
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NCI_THESAURUS C357
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000175488
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
LIVERTOX NBK548666
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
WHO-VATC QJ51DB04
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
NDF-RT N0000011161
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
WHO-VATC QJ01DB04
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
Code System Code Type Description
RS_ITEM_NUM
1097603
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
CHEBI
474053
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
DRUG CENTRAL
530
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
ChEMBL
CHEMBL1435
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
NCI_THESAURUS
C28913
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
WIKIPEDIA
CEFAZOLIN
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
PUBCHEM
33255
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
LACTMED
Cefazolin
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
RXCUI
2180
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY RxNorm
MESH
D002437
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
ECHA (EC/EINECS)
247-362-8
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
EPA CompTox
DTXSID2022753
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
CAS
25953-19-9
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
EVMPD
SUB07379MIG
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
DRUG BANK
DB01327
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
DAILYMED
IHS69L0Y4T
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
INN
2991
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
MERCK INDEX
M3188
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY Merck Index
HSDB
3213
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
FDA UNII
IHS69L0Y4T
Created by admin on Fri Dec 16 16:50:17 UTC 2022 , Edited by admin on Fri Dec 16 16:50:17 UTC 2022
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC